Navigation Links
BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update
Date:10/31/2008

st can be accessed by logging onto http://www.biocryst.com. Please connect to the Web site at least 15 minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary.

About BioCryst

BioCryst is an integrated biopharmaceutical company utilizing crystallography and structure-based drug design to develop a deep pipeline of novel therapeutics targeting major illnesses. BioCryst is currently advancing investigational new drugs discovered in-house in late-stage clinical trials for influenza and lymphoma. In addition, the Company has a pre-clinical portfolio of novel compounds, directed against infectious, cardiovascular, and autoimmune disease targets, to create long-term sustainable value. The Company's strategic alliances with the U.S. Department of Health and Human Services, Shionogi & Co., Ltd., Green Cross Corporation and Mundipharma International Holdings Ltd. validate its scientific foundation and the utility of its product candidates. For more information, please visit the Company's Web site at http://www.biocryst.com.

Forward-looking statements

This press release contains forward-looking statements, including statements regarding future results, performance or achievements. These statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. These statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Some of the factors that could affect the forward-looking statements contained herein in
'/>"/>

SOURCE BioCryst Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioCryst Reports Results From the First-Ever Completed Active-Controlled Phase 2 Study in Hospitalized Influenza
2. BioCryst Pharmaceuticals To Announce Third Quarter 2008 Financial Results On October 31, 2008
3. BioCryst to Present at the JMP Healthcare Focus Conference
4. BioCryst to Present at UBS 2008 Global Life Sciences Conference
5. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
6. William P. Sheridan Appointed Chief Medical Officer of BioCryst Pharmaceuticals
7. BioCryst Reports First Quarter 2008 Financial Results and Clinical Update
8. BioCryst Reports Fourth Quarter and Year End 2007 Financial Results and Corporate Update
9. BioCryst Pharmaceuticals to Announce Fourth Quarter and Fiscal Year 2007 Financial Results on March 4, 2008
10. BioCryst Strengthens Its Expertise in Clinical Development By Adding Thomas J. Simon, M.D. as Interim Chief Medical Officer To Meet Growing Product Development and Commercial Opportunities
11. BioCryst to Present at UBS 2007 Global Life Sciences Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/15/2014)... 15 septembre 2014 La deuxième édition ... (semaine internationale sur la sensibilisation au plasma) ... conjointe de la Plasma Protein Therapeutics Association ... , l,IPAW vise à : , ... la collecte du plasma-aphérèse , Reconnaître la ...
(Date:9/15/2014)... ANNAPOLIS, Md. , Sept. 15, 2014  The ... will be celebrated October 12-18. A joint initiative of ... its member companies , IPAW is designed to: ... collection , Recognize the contributions of plasma donors ... about lifesaving plasma protein therapies and rare diseases ...
(Date:9/14/2014)... UMBC’s Biotechnology Graduate Programs’ Virtual Information ... from 12:00 to 1:00 p.m. EDT. The session will ... practice-oriented instruction, designed for working professionals. Participants will also ... career in the biotechnology industry. , If interested in ... UMBC’s Biotechnology Graduate Programs, UMBC offers a variety of ...
(Date:9/14/2014)... particularly ingenious when it comes to survival strategies. They ... hostile environment, for example during treatment with antibiotics. A ... a protective slime capsule consisting of sugar chains and ... have for the first time created a detailed three-dimensional ... blocks cross the bacterial cell wall, a crucial step ...
Breaking Biology Technology:L' International Plasma Awareness Week célébrera les donneurs et braquera les projecteurs sur les maladies rares 2L' International Plasma Awareness Week célébrera les donneurs et braquera les projecteurs sur les maladies rares 3International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 2International Plasma Awareness Week To Celebrate Donors And Spotlight Rare Diseases 3UMBC Biotechnology Graduate Programs’ Virtual Info Session, October 21, 2014 2New insights in survival strategies of bacteria 2
... , , BOULDER, Colo. and THOUSAND OAKS, Calif., Dec. 14 ... AMGN ) today announced that they entered into an agreement ... including ARRY-403, currently being tested in a Phase 1 clinical trial ... terms of the agreement, Array will receive an upfront payment of ...
... , , JUPITER, Fla., Dec. ... today that it has extended its collaboration with The Scripps ... to re-annotate the genome of Dyadic,s patented and proprietary C1 ... successful relationship between the two organizations which began in March ...
... , ROCKAWAY, N.J., Dec. 14 ... Evidence-Based Approach , published by the Infusion ... anthracycline extravasation.(1) Anthracyclines are a group of chemotherapy medications ... in the treatment of various types of cancer since the ...
Cached Biology Technology:Array BioPharma and Amgen Partner in Type 2 Diabetes 2Array BioPharma and Amgen Partner in Type 2 Diabetes 3Array BioPharma and Amgen Partner in Type 2 Diabetes 4Array BioPharma and Amgen Partner in Type 2 Diabetes 5Array BioPharma and Amgen Partner in Type 2 Diabetes 6Array BioPharma and Amgen Partner in Type 2 Diabetes 7Dyadic International Extends Collaboration With The Scripps Research Institute 2Dyadic International Extends Collaboration With The Scripps Research Institute 3Dyadic International Extends Collaboration With The Scripps Research Institute 4Dyadic International Extends Collaboration With The Scripps Research Institute 5Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 2Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 3Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 4Infusion Nurses Society References Totect(R) (Dexrazoxane For Injection) as the Only Antidote for the Treatment of Anthracycline Extravasation 5
(Date:9/15/2014)... hearing and cognitive function may play roles in one,s ... rhythm, pitch, timbre, tone durations, and formal structure in ... article explain that extremes in musical aptitude (extreme capacity/no ... of individuals having moderate aptitude. , "This is a ... underlying genes, and it is influenced to varying degrees ...
(Date:9/15/2014)... the subsequent rapid decrease in the water level of ... square kilometres of new, fertile land in eastern Finland. ... researchers has studied the role that the decrease in ... and humans. After dramatic shifts in the waterways, human ... rise to a new, innovative culture. This stemmed from ...
(Date:9/15/2014)... Sharks, swamps and a tropical rainforest teeming with life ... Yorkshire, England. But for the first time evidence of Doncaster,s ... discovered in a derelict mining tip. , Some of the ... and as well as the egg case, several horseshoe crabs ... All had been preserved in rocks that formed within ...
Breaking Biology News(10 mins):The creation of the Vuoksi River preceded a significant cultural shift 2'Jaws' lived in Doncaster 2
... its wood and cottony fibers, the kapok tree now ... for decades: the notion that African and South American ... million years ago. , Research by University of Michigan ... perhaps other rainforest--trees colonized Africa after the continents split ...
... modification to successfully manipulate the growth in height of trees, ... similar to normal trees – but after several years of ... few inches. , This is a “proof of concept” that ... It opens the door to a wide variety of new ...
... that will be published online in advance of its July ... colleagues (The Salk Institute and HHMI) demonstrate that endosomes can ... animals. , "These findings will influence our thinking of the ... why cells use them as signaling compartments," noted lead author ...
Cached Biology News:The kapok connection -- Study explains rainforest similarities 2Researchers demonstrate way to control tree height 2Researchers demonstrate way to control tree height 3
... for use as a wash buffer for Michels ... is useful for transportation of specimens (such as ... Samples may remain in Transport Fluid for ... Michels Transport Fluid is not a fixative and ...
... use with 96- or 384-well PCR plates Dimples ... location on 96-tube plates End tabs on Thermo-Mat™ ... plate* Efficient sealing is achieved with either Thermo-Mat™ ... or clip-down hot lid thermal cyclers Fully autoclavable ...
... TUNEL-based assay kit provides complete components including ... detection of DNA fragmentation in cultured cells ... in the procedure provides greater sensitivity than ... analyzed by flow cytometry. The kit works ...
... Buffer is a unique alternative to ... (TRIS acetate-EDTA) electrophoresis buffers. Bionic Buffer ... rapid running times, and high-resolution band ... gel electrophoresis after dilution to working ...
Biology Products: